Download Free Integrative Pharmacology Book in PDF and EPUB Free Download. You can read online Integrative Pharmacology and write the review.

ntegrative Pharmacology can be used to determine the multi-pharmacological effects of traditional medicines such as traditional Chinese medicine (TCM), Kampo, Sa-sang, Ayurveda, etc.). Through qualitative and quantitative pharmacokinetic-pharmacodynamic (PK-PD) correlations among multi-constituents and multi-targets, integrating chemical profiling, ADME/PK processes, molecular network calculation and resulting experimental validation, the use of Integrative Pharmacology has become widespread. The data has provided a novel paradigm to evaluate the druggability of bioactive ingredients of herbs or formulae, to decipher the pharmacological mechanisms of drug action and to screen potentially new indications for approved drugs and previously unidentified adverse events. On this basis, Integrative Pharmacology may offer an effective way to test the potential scientific basis for traditional medicines and to assess what roles of traditional medicine can and cannot play in pharmaceuticals.
There is a growing interest in unmet needs for the development of a new discipline in drug discovery and in university education on polypharmacology. However, there has not been a book with the comprehensive compilation of basic knowledge and advanced methodology that is needed. This book aims to meet the needs making Polypharmacology a new sub-discipline of Pharmacology, not only being a hot area of pharmacological research and education but also a new paradigm for drug discovery. It contains the contents covering the entire scope of Polypharmacology including systemic in-depth exposition of basic knowledge, novel concepts, innovative technologies, and translational and clinical applications by showcasing state-of-the-art strategies and step-by-step instructions of cutting-edge methods. The contents of this book targets broad readerships including scientists in pharmacology research and drug development, and university teachers and graduates in medical school or school of pharmacy.
This book provides a holistic view of natural products and remedies that have been used to treat cancer. The editors aim to educate readers about the importance of the translational role of natural products in cancer treatment by compiling 14 chapters. The book emphasizes an integrative approach to the topic by blending traditional knowledge that supports alternative therapies with the science of phytochemicals and drug discovery technologies as a means to manage the disease. Key topics include alternative therapies (such as aromatherapy and immune boosting herbal medications), cytotoxic and anti-cancer phytochemicals, drug delivery and discovery technologies (including high-throughput screening) and some drug targets of interest for cancer treatment (such as topoisomerases and caspases). Readers will be able to learn about natural sources of ant-cancer compounds, and the methods used by research and development experts in pharmaceutical and nutraceutical industries to isolate and formulate these compounds. This book will be a handy resource for a wide range of readers. This includes researchers, traditional medical practitioners, PG students, Ph.D. scholars and general readers to understand the role of natural products in cancer treatment. key features - Explains the importance of alternative therapies in the management of cancer - Emphasizes the ethnopharmacological approaches to cancer - Explores natural anticancer drug libraries - Discusses the role of modern cancer targets and the importance of in-silico tools in anticancer drug discovery - Addresses modern drug discovery tools and drug delivery technologies concerning their applications in cancer treatment. - Includes references for further reading
This one-stop reference is the first to present the complete picture -- covering all relevant organisms, from single cells to mammals, as well as all major disease areas, including neurological disorders, cancer and infectious diseases. Addressing the needs of the pharmaceutical industry, this unique handbook adopts a broad perspective on the use of animals in the early part of the drug development process, including regulatory rules and limitations, as well as numerous examples from real-life drug development projects. After a general introduction to the topic, the expert contributors from research-driven pharmaceutical companies discuss the basic considerations of using animal models, including ethical issues. The main part of the book systematically surveys the most important disease areas for current drug development, from cardiovascular to endocrine disorders, and from infectious to neurological diseases. For each area, the availability of animal models for target validation, hit finding and lead profiling is reviewed, backed by numerous examples of both successes and failures among the use of animal models. The whole is rounded off with a discussion of perspectives and challenges. Key knowledge for drug researchers in industry as well as academia.
Each volume of Advances in Pharmacology provides a rich collection of reviews on timely topics. Emphasis is placed on the molecular basis of drug action, both applied and experimental. - Articles written by leading investigators in the field - Informs and updates on all the latest developments
This book helps readers integrate in silico, in vitro, and in vivo ADMET (absorption, distribution, metabolism, elimination and toxicity) and PK (pharmacokinetics) data with routine testing applications so that pharmaceutical scientists can diagnose ADMET problems and present appropriate recommendations to move drug discovery programs forward. The book introduces the current clinical practice for drug discovery and development along with the impact on early risk assessment; consolidates the tools and models to intelligently integrate existing in silico, in vitro and in vivo ADMET data; and demonstrates successful cases and lessons learned from real drug discovery and development. In short, it is a book aimed to provide a practical road map for drug discovery and development scientists to generate efficacious and safe drugs for unmet medical needs.
This one-stop reference systematically covers key aspects in early drug development that are directly relevant to the discovery phase and are required for first-in-human studies. Its broad scope brings together critical knowledge from many disciplines, ranging from process technology to pharmacology to intellectual property issues. After introducing the overall early development workflow, the critical steps of early drug development are described in a sequential and enabling order: the availability of the drug substance and that of the drug product, the prediction of pharmacokinetics and -dynamics, as well as that of drug safety. The final section focuses on intellectual property aspects during early clinical development. The emphasis throughout is on recent case studies to exemplify salient points, resulting in an abundance of practice-oriented information that is usually not available from other sources. Aimed at medicinal chemists in industry as well as academia, this invaluable reference enables readers to understand and navigate the challenges in developing clinical candidate molecules that can be successfully used in phase one clinical trials.
PROFILES POTENTIAL TREATMENT APPROACHES FOR CARDIAC ARRHYTHMIAS Cardiac arrhythmias of ventricular origin are responsible for the deaths of nearly half a million Americans each year while atrial fibrillation accounts for about 2.3 million cases per year, a rate that is projected to increase 2.5 fold over the next half century. Effectively managing these cardiac rhythm disorders remains a major challenge for both caregivers and the pharmaceutical industry. Filling a gap in the current literature, Novel Therapeutic Targets for Antiarrhythmic Drugs presents the latest treatments for cardiac arrhythmias alongside comprehensive presentations of basic cardiac physiology and pharmacology. Written by leading experts in their research areas, this invaluable resource offers both practitioners and researchers a one-stop guide that brings together previously dispersed information. The text consists of four sections: Section One comprehensively reviews basic cardiac electrophysiology, the mechanisms responsible for arrhythmias in the setting of ischemia, and basic pharmacology of antiarrhythmic drugs. Section Two addresses safety pharmacology, including the concept of "repolarization reserve," safety challenges, and regulatory issues for the development of novel antiarrhythmic drugs. Section Three describes several novel pharmacological targets for antiarrhythmic drugs, including both ion channel and non-ion channel targets. Section Four describes promising non-pharmacological antiarrhythmic interventions including selective cardiac neural disruption or nerve stimulation, aerobic exercise training, and diet (omega-3 fatty acids). Offering an unparalleled look at the current state and future direction of cardiac arrhythmia treatment, Novel Therapeutic Targets for Antiarrhythmic Drugs provides an important resource to advanced students, working researchers, and busy professionals alike.
With its focus on emerging concerns of kinase and GPCR-mediated antitarget effects, this vital reference for drug developers addresses one of the hot topics in drug safety now and in future. Divided into three major parts, the first section deals with novel technologies and includes the utility of adverse event reports to drug discovery, the translational aspects of preclinical safety findings, broader computational prediction of drug side-effects, and a description of the serotonergic system. The main part of the book looks at some of the most common antitarget-mediated side effects, focusing on hepatotoxicity in drug safety, cardiovascular toxicity and signaling effects via kinase and GPCR anti-targets. In the final section, several case studies of recently developed drugs illustrate how to prevent anti-target effects and how big pharma deals with them if they occur. The more recent field of systems pharmacology has gained prominence and this is reflected in chapters dedicated to the utility in deciphering and modeling anti-targets. The final chapter is concerned with those compounds that inadvertently elicit CNS mediated adverse events, including a pragmatic description of ways to mitigate these types of safety risks. Written as a companion to the successful book on antitargets by Vaz and Klabunde, this new volume focuses on recent progress and new classes, methods and case studies that were not previously covered.